Recombinant Zoster Vaccination Among US Veterans Receiving Immunosuppressives
Sharon Abada,Jing Li,Gary Tarasovsky,Cherish Wilson,Jinoos Yazdany,Mary A. Whooley,Gabriela Schmajuk
DOI: https://doi.org/10.1001/jamanetworkopen.2024.39945
2024-10-12
JAMA Network Open
Abstract:Individuals who are immunocompromised, including those receiving immunosuppressive medications, have an increased risk of herpes zoster and associated complications compared with the general population; those receiving targeted synthetic disease modifying agents (tsDMARDs), such as Janus kinase inhibitors, are at particularly increased risk. 1 ,2 In 2017, the Food and Drug Administration (FDA) approved a recombinant zoster vaccine (RZV) for individuals aged 50 years or older. In 2021, the FDA additionally approved RZV for adults aged 18 years and older who are immunocompromised, and the Centers for Disease Control and Prevention and American College of Rheumatology issued updated guidance in 2021 and 2022, respectively. 3 -5 However, there is little published evidence regarding RZV vaccination among US adults who are immunocompromised, particularly those younger than 50 years. We assessed RZV receipt among veterans receiving immunosuppressive medications within the Veterans Health Administration (VHA) health care system before and after expanded indications. This cross-sectional study was approved by the VA Quality Enhancement Research Initiative and University of California San Francisco institutional review board with a waiver of informed consent as a minimal-risk study. It used nationwide VHA data among veterans at 130 medical facilities prescribed 1 or more immunosuppressive medications for 90 days or more between January 1, 2018, and June 30, 2023. The outcome was the percentage of veterans with 1 or more RZV doses documented during the study period, assessed before the expanded indication (January 2018 to February 2022) and at any time (January 2018 to June 2023). To examine factors associated with RZV receipt at any time, we constructed a multilevel regression model, including age, sex, self-identified race and ethnicity, rurality of residence, visits with more than 1 subspecialty (yes or no), receipt of 1 or more other vaccination at the VA (yes or no), and immunosuppressive medication type, accounting for clustering by facility using generalized estimating equations (eMethods in Supplement 1). Facility-level performance was reported as the percentage of veterans with 1 or more RZV doses documented among those eligible at any time. Analyses were performed using Stata statistical software version 16 (StataCorp) (eMethods in Supplement 1). We followed the STROBE reporting guideline. We identified 190 162 veterans receiving immunosuppressive medications across 130 facilities during the study period. By the end of the study period, 23 295 veterans (12.3%) were younger than 50 years (characteristics shown in Table 1). Among veterans aged 50 years or older, 55 546 of 153 620 individuals (36.2%) had an RZV before the expanded indication and 83 117 of 166 867 individuals (49.8%) had it by mid-2023. Among veterans younger than 50 years, 638 of 22 631 individuals (2.8%) had an RZV before the expanded indication and 3118 of 23 295 individuals (13.4%) had it by mid-2023. Demographic factors associated with lower odds of vaccination included male sex, African American and unknown race, and nonurban residence (Table 2). Factors associated with increased odds of vaccination included treatment with tsDMARDs and other measures of increased health care use (Table 2). Across VA facilities, the percentage of veterans with 1 or more RZV doses at any time ranged from 17.7% to 71.1%. To our knowledge, this cross-sectional study is the first study to examine RZV receipt in a large population of adults, including those younger than 50 years, receiving immunosuppressive medications. Overall, less than half of veterans in the US taking chronic immunosuppressive medications received even 1 dose of RZV; for patients younger than 50 years, percentages were much lower. Although vaccination rates among these older veterans at high risk were higher than those in the 2021 National Health Interview Survey (18.6% for US adults aged ≥50 years), 6 there remains substantial room for improvement. This study may not be generalizable to nonveteran populations or non-US countries. Limitations also include difficulty with capture of vaccinations not administered within the VHA system, which may result in an underestimate of the percentage of patients vaccinated. Future work to improve RZV vaccination in patients at high risk should focus on creating informatics tools to identify individuals at high risk and standardizing vaccination guidelines across subspecialties. Accepted for Publication: August 25, 2024. Published: October 11, 2024. doi:10.1001/jamanetworkopen.2024.39945 Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2024 Abada S et al. JAMA Network Open . Corresponding Author: Gabriela Schmajuk, MD, MS, University of C -Abstract Truncated-
medicine, general & internal